1. Home
  2. PETS vs ACRS Comparison

PETS vs ACRS Comparison

Compare PETS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PETS
  • ACRS
  • Stock Information
  • Founded
  • PETS 1996
  • ACRS 2012
  • Country
  • PETS United States
  • ACRS United States
  • Employees
  • PETS N/A
  • ACRS N/A
  • Industry
  • PETS Retail-Drug Stores and Proprietary Stores
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PETS Consumer Staples
  • ACRS Health Care
  • Exchange
  • PETS Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • PETS 87.1M
  • ACRS 94.1M
  • IPO Year
  • PETS N/A
  • ACRS 2015
  • Fundamental
  • Price
  • PETS $3.96
  • ACRS $1.35
  • Analyst Decision
  • PETS Buy
  • ACRS Hold
  • Analyst Count
  • PETS 2
  • ACRS 6
  • Target Price
  • PETS $5.25
  • ACRS $11.50
  • AVG Volume (30 Days)
  • PETS 465.5K
  • ACRS 1.5M
  • Earning Date
  • PETS 08-06-2024
  • ACRS 08-05-2024
  • Dividend Yield
  • PETS 7.63%
  • ACRS N/A
  • EPS Growth
  • PETS N/A
  • ACRS N/A
  • EPS
  • PETS N/A
  • ACRS N/A
  • Revenue
  • PETS $281,064,000.00
  • ACRS $31,119,000.00
  • Revenue This Year
  • PETS $2.07
  • ACRS N/A
  • Revenue Next Year
  • PETS $4.31
  • ACRS N/A
  • P/E Ratio
  • PETS N/A
  • ACRS N/A
  • Revenue Growth
  • PETS 9.54
  • ACRS 0.95
  • 52 Week Low
  • PETS $3.63
  • ACRS $0.59
  • 52 Week High
  • PETS $15.08
  • ACRS $10.15
  • Technical
  • Relative Strength Index (RSI)
  • PETS 45.43
  • ACRS 64.88
  • Support Level
  • PETS $3.77
  • ACRS $1.26
  • Resistance Level
  • PETS $3.94
  • ACRS $1.42
  • Average True Range (ATR)
  • PETS 0.16
  • ACRS 0.06
  • MACD
  • PETS 0.01
  • ACRS 0.01
  • Stochastic Oscillator
  • PETS 44.00
  • ACRS 76.09

About PETS PetMed Express Inc.

PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Share on Social Networks: